GSA Capital Partners’s Citius Pharmaceuticals CTXR Stock Holding History

GSA Capital Partners’s Portfolio CTXR Stock Details CTXR Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q4	–	Sell	-7,940	Closed	-$136K	–	1561
2023 Q3	$136K	Sell	7,940 -7,024	-47%	-$167K	0.01%	1358
2023 Q2	$449K	Sell	14,964 -3,138	-17%	-$103K	0.04%	811
2023 Q1	$529K	Sell	18,102 -1,849	-9%	-$53.3K	0.05%	674
2022 Q4	$394K	Buy	19,951 +14,295	+253%	+$390K	0.05%	751
2022 Q3	$171K	Buy	+5,656	New	+$155K	0.02%	1275
2021 Q3	–	Sell	-1,786	Closed	-$155K	–	1498
2021 Q2	$155K	Sell	1,786 -513	-22%	-$30.8K	0.02%	1216
2021 Q1	$102K	Buy	2,299 +946	+70%	+$37.7K	0.02%	1000
2020 Q4	$35K	Buy	+1,353	New	+$35.3K	0.01%	1144

Other funds holding CTXR

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Northern Trust Chicago, Illinois $860B AUM 41.15% 1-Year Est. Return

Osaic Holdings Scottsdale, Arizona $85.1B AUM 27.35% 1-Year Est. Return

Nuveen Charlotte, North Carolina $419B AUM 43.02% 1-Year Est. Return

Charles Schwab San Francisco, California $751B AUM 38.74% 1-Year Est. Return

Bank of New York Mellon New York $609B AUM 40.19% 1-Year Est. Return

Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

GSA Capital Partners's CTXR Position: Q4 2023 in Review

GSA Capital Partners sold out of Citius Pharmaceuticals (CTXR) in Q4 2023, closing a stake of 7,940 shares — an estimated $136K sold.

GSA Capital Partners first reported a position in CTXR in Q4 2020 and held it in 8 quarters. The position peaked at $529K in Q1 2023. 74 funds tracked by Wall St. Rank hold CTXR as of Q4 2023.

GSA Capital Partners reported no remaining Citius Pharmaceuticals position as of Q4 2023 after selling out during the quarter.
GSA Capital Partners sold 7,940 Citius Pharmaceuticals shares in Q4 2023, an estimated $136K.
GSA Capital Partners first reported a position in Citius Pharmaceuticals in Q4 2020 and held it in 8 quarters.
GSA Capital Partners's Citius Pharmaceuticals position peaked at $529K in Q1 2023.
74 funds tracked by Wall St. Rank held Citius Pharmaceuticals as of Q4 2023.

Based on GSA Capital Partners's 13F filing for Q4 2023, filed 16 Feb 2024.